Safety and clinical analysis of Zongatinib (Zongatinib)

Zongertinib (trade name: Zongertinib) is a new oral targeted drug mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Its mechanism of action is to achieve anti-tumor effects by inhibiting the activity of EGFR mutant tyrosine kinase and blocking tumor cell proliferation and survival signals. Clinical trials have shown that zongatinib can significantly prolong progression-free survival and improve the quality of life of some patients in patients who have failed or are resistant to previous standard treatments, showing good clinical potential.

In terms of safety, zongatinib is generally well tolerated, but certain adverse reactions may still occur. Common side effects include rash, diarrhea, nausea, fatigue, and mild increases in liver function parameters. Most adverse reactions are mild to moderate and can be alleviated by symptomatic treatment or dose adjustment. For patients with hematology or liver function abnormalities, it is recommended to conduct basic examinations before taking medication, and to regularly monitor blood routine and liver function during treatment, so that abnormalities can be detected early and intervention measures can be taken.

Clinical analysis shows that the efficacy of zongertinib is closely related to individual patient characteristics and tumor genotype. EGFR 20Patients with exon insertion mutations have shown significant improvements in objective response rate and disease control rate after treatment with zongertinib, but the efficacy may still vary due to individual differences. Some patients may develop drug resistance during long-term medication. At this time, it is necessary to consider combined treatment or adjust the plan based on the results of molecular testing to extend the duration of the therapeutic effect.

Patients should pay attention to rational medication use and risk management when using zongatinib. First of all, you should take the medicine strictly in accordance with the doctor's prescription, and you should not increase or decrease the dose at will or stop the medicine on your own; secondly, pregnant and lactating women should use it with caution to avoid potential risks; in addition, attention should be paid to the interaction between the medicine and other oral drugs, especially CYP3A4 metabolism-related drugs to prevent abnormal blood drug concentration. Overall, zongatinib has significant efficacy and controllable safety in precision targeted therapy, but it requires standardized use and long-term follow-up under the guidance of professional physicians to ensure drug safety and maximize efficacy.

Reference materials:https://www.drugs.com/